AlphAIAlphAI — Financial news for AI agents
stocktitan.netAUG 211 min read$PALI

Palisade Bio (PALI) CEO reallocates 176K shares in gifts

Palisade Bio (PALI) CEO John David Finley gifted 176,800 shares of common stock on August 19, 2026, transferring 88,400 shares to FCW Investments, LLC, which he manages. Post-transaction, he directly holds 129,288 shares and indirectly holds 88,451 shares. The transactions were not under a Rule 10b5-1 trading plan.

Original reporting
stocktitan.net
Published Aug 21, 2026, 10:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 7:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PALI
Neutral
medium confidence
Mentioned
$PALI
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PALINeutralLow
01

Why it matters

The filing provides a fresh, primary source of insider activity, but the material impact on price is expected to be limited.

02

Market read

Primary insider disclosure with modest relevance; likely low trading urgency.

03

What to watch

Absence of a 10b5‑1 plan may raise governance concerns among institutional investors.

Relevance 4/10Novelty 5/10Timing: after‑hours Aug 19 2026

Background

Form 4 filing discloses insider transactions; gifts are reported without a monetary value and are not executed under a pre‑arranged trading plan.

Company-level read

Ticker impact

$PALINeutralMedium confidence
Context

CEO/CFO John David Finley gifted 176,800 shares of Palisade Bio, reallocating holdings between direct and indirect ownership.

Expected impact

Minimal short‑term impact; market may view the lack of a 10b5‑1 plan as a slight negative.

Evidence & confidence

Gift transactions are disclosed on Form 4 and are primary information, yet the size relative to market cap is modest and no cash changed hands.

Market effects

Sector

None; the filing is company‑specific and does not affect the broader biotech sector.

Regional

None; the news is limited to Palisade Bio investors.

Global

None

Counterpoint

What could challenge this read

The gift could signal confidence in the company's future, potentially supporting a modest upside view.

Key entities

  • individual
    John David Finley

    CEO and CFO of Palisade Bio, responsible for the disclosed gift transactions.

  • entity
    FCW Investments, LLC

    Entity managed by Finley that now holds 88,451 shares indirectly.

Read at source← All news

Related articles

OCT 28
$PALILowAI 8/10

Palisade Bio doses first patient in ulcerative colitis trial

Palisade Bio Inc. (PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis, evaluating PALI-2108. The trial aims to enroll 204 patients and has 29 U.S. sites active, with global expansion ongoing. Topline results are expected in Q4 2027. PALI-2108 is an investigational oral PDE4 inhibitor prodrug. The company also conducts a Phase 2 study for Crohn’s disease.

investing.com1 min
OCT 21
$PALIMedAI 8/10

Oppenheimer reiterates Palisade Bio stock rating on Crohn’s data

Oppenheimer reiterated an Outperform rating and $8.00 price target on Palisade Bio (NASDAQ:PALI) after additional data from UEG Week. The stock is down 49% over six months but has a Strong Buy consensus and targets ranging from $5 to $25. New tissue analyses showed reduced PDE4D expression and signs of tissue remodeling. Phase 2 trials are ongoing, with data expected in 2H27. Other analysts also reiterated or initiated positive ratings.

investing.com2 min
OCT 20
$PALIMedAI 8/10

Palisade Bio reports early-stage Crohn’s disease trial results

Palisade Bio (NASDAQ:PALI) reported early-stage trial results for PALI-2108, showing reductions in Crohn's disease activity measures in a small, 5-patient study. The drug demonstrated decreases in disease scores and inflammation markers, with mild adverse events. The company is advancing to Phase 2 studies. Results are preliminary and require further validation.

investing.com1 min